China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $111.67 for the company and are predicting that the company will post $1.11 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 193 out of 265 based on the ratings given to its competitors.
CBPO has been the topic of several analyst reports. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. BidaskClub upgraded China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 20th.
China Biologic Products (NASDAQ CBPO) opened at $79.10 on Monday. The firm has a market capitalization of $2,620.58, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.00 and a beta of 1.67. China Biologic Products has a 52-week low of $72.21 and a 52-week high of $120.46.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.